Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant NALIRINOX with KRAS liquid biopsy monitoring in resectable pancreatic ductal adenocarcinoma
2018-002094-22Phase 2Active
- Sponsor
- HM Hospitales
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, oxaliplatin, folinic acid and fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by HM Hospitales. Started Jan 2019; status: active.
02
Drugs
irinotecan liposomeoxaliplatinfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2018-002094-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002094-22.